机构：[1]MR and CT Contrast Media Research, Bayer HealthCare, Berlin, Germany[2]Global Medical Affairs Radiology, Bayer HealthCare, Berlin, Germany[3]Saarland University Hospital, Homburg, Germany[4]Medical Imaging, Coimbra Hospital and University Centre, Coimbra, Portugal[5]Radiology, Medical Physics and Biomedical Engineering, University of Wisconsin, Madison, WI, USA[6]Radiology and Neurological Surgery, University of South California, Keck School of Medicine, USC University Hospital, Los Angeles, CA, USA[7]College of Medicine, Seoul National University Hospital, Seoul, South Korea[8]Radiology, Utrecht University Medical Center, Utrecht, The Netherlands[9]Radiology, Xuan Wu Hospital, Capital Medical University, Beijing, People’s Republic of China放射科首都医科大学宣武医院[10]Radiology, Ludwig-Maximilians University, University Hospitals, Munich, Germany[11]Radiology, Weill Cornell Medical College, New York, NY, USA[12]Columbia College of Physicians and Surgeons, New York, NY, USA[13]Radiology, University of Bonn, Bonn, Germany[14]Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA[15]Graduate Division of Medical Health Sciences, Graduate School of Komazawa University, Tokyo, Japan
In 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist(A (R))), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives. Bayer HealthCare.
基金：
the open access charge for this study were funded by Bayer HealthCare.
语种：
外文
高被引：
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2015]版：
大类|3 区医学
小类|4 区医学：研究与实验4 区药学
最新[2023]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
JCR分区：
出版当年[2014]版：
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3PHARMACOLOGY & PHARMACY
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2PHARMACOLOGY & PHARMACY
第一作者机构：[1]MR and CT Contrast Media Research, Bayer HealthCare, Berlin, Germany
通讯作者：
通讯机构：[1]MR and CT Contrast Media Research, Bayer HealthCare, Berlin, Germany
推荐引用方式(GB/T 7714)：
Jessica Lohrke,Thomas Frenzel,Jan Endrikat,et al.25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives[J].ADVANCES IN THERAPY.2016,33(1):1-28.doi:10.1007/s12325-015-0275-4.
APA：
Jessica Lohrke,Thomas Frenzel,Jan Endrikat,Filipe Caseiro Alves,Thomas M. Grist...&Hubertus Pietsch.(2016).25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.ADVANCES IN THERAPY,33,(1)
MLA：
Jessica Lohrke,et al."25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives".ADVANCES IN THERAPY 33..1(2016):1-28
